Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Nkarta, Inc. NKTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
58/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.60
+843.2%

Nkarta, Inc. (NKTX) is a Biotechnology company in the Healthcare sector, currently trading at $2.29. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is NKTX = $22 (+843.2% upside).

Valuation: NKTX trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.04.

Net income is $104M (loss), growing at +2.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $76M against $312M equity (Debt-to-Equity (D/E) ratio 0.24, conservative). Current ratio is 12.69 (strong liquidity). Debt-to-assets is 18.9%. Total assets: $404M.

Analyst outlook: 10 / 12 analysts rate NKTX as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 83/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$21.60
▲ 843.23% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Nkarta, Inc., the average price target is $21.60, with a high forecast of $36.00, and a low forecast of $15.00.
Highest Price Target
$36.00
Average Price Target
$21.60
Lowest Price Target
$15.00

NKTX SharesGrow Score Overview

70/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 83/100
Valuation — P/E, PEG, Forward PEG
GROWTH 45/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NKTX

✓
VALUE Pass
83/100
NKTX trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25). Forward PEG 1.04 — ~moderate (~1.5). Trailing PEG 1.13. Analyst consensus target is $22, implying +860.7% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
45/100
NKTX: +0%/yr revenue is, +2.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NKTX: Debt-to-Equity (D/E) ratio 0.24 (conservative), Current ratio is 12.69 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NKTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 10 / 12 analysts rate NKTX as buy (83%). Analyst consensus target is $22 (+860.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.42-2.81
Volume535.93K
Avg Volume (30D)718.73K
Market Cap$163.26M
Beta (1Y)0.67
Share Statistics
EPS (TTM)-1.41
Shares Outstanding$73.99M
IPO Date2020-07-10
Employees157
CEOPaul J. Hastings
Financial Highlights & Ratios
Gross Profit$-9.19M
EBITDA$-112.01M
Net Income$-104.08M
Operating Income$-121.21M
Total Cash$276.28M
Total Debt$76.42M
Net Debt$36.79M
Total Assets$404.21M
Price / Earnings (P/E)-1.6
Analyst Forecast
1Y Price Target$16.00
Target High$36.00
Target Low$15.00
Upside+598.7%
Rating ConsensusBuy
Analysts Covering12
Buy 83% Hold 17% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS65487U1088

Price Chart

Track all markets on TradingView
NKTX
Nkarta, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.42 52WK RANGE 2.81

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 HARP
HARP
Harpoon Therapeutics, Inc.
$23.01
+0.09%
 LYEL
LYEL
Lyell Immunopharma, Inc.
$23.37
-5.77%
 ALEC
ALEC
Alector, Inc.
$2.41
+3.43%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.37
+4.41%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message